Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB2004 Trial for Risk Adapted Treatment of Children With Neuroblastoma
NCT00410631Phase 3Unknown
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Oct 2004
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of topotecan in neuroblastoma (4 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
topotecan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00410631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410631.